


EVOTEC AG

ISIN: DE0005664809 WKN: 566480 Asset Class: Stock

Company 2023/06/08 17:36:22

Price
22.86
 EUR

Difference ↑
 8.39%(1.77)



Contact Details

EVOTEC SE Tel: +49-40-56081-0
 -- Fax: +49-40-56081-222
 Manfred Eigen Campus, Essener Bogen 7 Web: <http://evotec.com>
 22419 Hamburg E-mail: info@evotec.com

Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	1,073,671,000		1,100,940,000		658,844,000	
Common stock capital		176,953,000		176,608,000		163,915,000
Fixed assets	1,232,464,000		1,175,323,000		843,633,000	
Equity capital of a company		1,187,184,000		1,377,685,000		722,846,000
Cash and cash equivalents	415,155,000		699,326,000		422,580,000	
Accrued liabilities		16,427,000		18,021,000		22,899,000
Other assets	-		-		-	
Current liabilities		337,706,000		324,516,000		208,459,000
Prepayments and accrued income		-		-		-
Non-current liabilities		781,245,000		574,062,000		571,172,000
Different income		-		-		-
Other liabilities		207,113,000		34,943,000		26,335,000
Total assets	2,306,135,000	2,306,135,000	2,276,263,000	2,276,263,000	1,502,477,000	1,502,477,000

Balance notes

	2022	2021	2020
Accounting standard	IFRS	IFRS	IFRS
Employees	4,952	4,198	3,572
Equity ratio	51.48%	60.52%	48.11%
Debt-equity ratio	94.25%	65.22%	107.86%

Others

	2022	2021	2020
Tax Expense Rate	11.72%	-4.75%	-52.04%

Income statement

	2022	2021	2020
Turnover	751,448,000	618,034,000	500,924,000
Net income	-175,655,000	215,510,000	6,252,000
EBIT	-176,079,000	228,532,000	18,101,000
Operating income before taxes	-180,893,000	221,550,000	10,975,000
Cash Flow	203,106,000	122,237,000	44,721,000
Net interest income	-4,814,000	-6,982,000	-7,126,000
Research and development expenses	76,642,000	72,200,000	63,945,000
Income taxes	-21,202,000	-10,530,000	-5,711,000
Result from investments in subsidiaries, associates and other	-15,964,000	-16,570,000	-10,434,000
Revenues per employee	151,746	147,221	140,236

Board of Directors

Iris Löw-Friedrich	Chairman of Supervisory Board
Constanze Ulmer-Eilfort	Member of Supervisory Board
Elaine Sullivan	Member of Supervisory Board
Mario Polywka	Member of Supervisory Board
Camilla Languille	Member of Supervisory Board
Roland Sackers	Member of Supervisory Board

Members of Management Board

Werner Lanthaler	Chairman of Managing Board
Cord Dohrmann	Member of Executive Committee
Craig Johnstone	Member of Executive Committee
Enno Spillner	Member of Executive Committee